Navigating Atopic Dermatitis: Tips from a Dermatologist to Help Manage the Most Common Type of Eczema
(BPT) - By BRANDPOINT
Source: kulr8.com
Page 10 - Medication Guidefor News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Medication Guidefor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Medication Guidefor Today - Breaking & Trending Today
New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of...
Source: prnewswire.com
Biogen Inc.: New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower
Source: finanznachrichten.de
Biogen Inc.: New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
Biogen Inc.: New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus (ocrelizumab) (diroximel fumarate) reinforce the treatment's positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021(Nasdaq: BIIB) today announc...
Source: finanznachrichten.de
Biogen Inc.: The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
(0) TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting The approval adds to Biogen's strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outcomes as part of the long-term treatment of patients with MS CAMBRIDGE, Mass., April 07, 2021(Nasdaq: BIIB) today announced ...
Source: finanznachrichten.de